Alvocade® (Bortezomib) Safety and Effectiveness Study

NCT06012383 · clinicaltrials.gov ↗

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma, Refractory

Interventions

DRUG: Bortezomib

Sponsor

NanoAlvand